JP2014502149A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502149A5
JP2014502149A5 JP2013538232A JP2013538232A JP2014502149A5 JP 2014502149 A5 JP2014502149 A5 JP 2014502149A5 JP 2013538232 A JP2013538232 A JP 2013538232A JP 2013538232 A JP2013538232 A JP 2013538232A JP 2014502149 A5 JP2014502149 A5 JP 2014502149A5
Authority
JP
Japan
Prior art keywords
arg
mutein
gly
trp
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502149A (ja
JP6100694B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/070119 external-priority patent/WO2012065978A1/en
Publication of JP2014502149A publication Critical patent/JP2014502149A/ja
Publication of JP2014502149A5 publication Critical patent/JP2014502149A5/ja
Application granted granted Critical
Publication of JP6100694B2 publication Critical patent/JP6100694B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538232A 2010-11-15 2011-11-15 グリピカン−3(gpc3)に対して親和性を有するヒトリポカリン2の突然変異タンパク質 Expired - Fee Related JP6100694B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41370610P 2010-11-15 2010-11-15
EP10191228.5 2010-11-15
EP10191228 2010-11-15
US61/413,706 2010-11-15
PCT/EP2011/070119 WO2012065978A1 (en) 2010-11-15 2011-11-15 Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Publications (3)

Publication Number Publication Date
JP2014502149A JP2014502149A (ja) 2014-01-30
JP2014502149A5 true JP2014502149A5 (cg-RX-API-DMAC7.html) 2015-01-08
JP6100694B2 JP6100694B2 (ja) 2017-03-22

Family

ID=45346426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538232A Expired - Fee Related JP6100694B2 (ja) 2010-11-15 2011-11-15 グリピカン−3(gpc3)に対して親和性を有するヒトリポカリン2の突然変異タンパク質

Country Status (7)

Country Link
US (1) US9260492B2 (cg-RX-API-DMAC7.html)
EP (1) EP2640740B1 (cg-RX-API-DMAC7.html)
JP (1) JP6100694B2 (cg-RX-API-DMAC7.html)
AU (1) AU2011331232B2 (cg-RX-API-DMAC7.html)
CA (1) CA2817779C (cg-RX-API-DMAC7.html)
DK (1) DK2640740T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012065978A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2564125C2 (ru) 2009-12-07 2015-09-27 Пирис Аг Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
SG10201912019WA (en) * 2014-05-22 2020-02-27 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
US11382963B2 (en) * 2015-01-12 2022-07-12 Pieris Pharmaceuticals Gmbh Engineered T cells and uses therefor
CA2973640A1 (en) 2015-01-28 2016-08-04 Rachida Siham Bel Aiba Novel proteins specific for angiogenesis
BR112017020434A2 (pt) 2015-05-04 2018-06-26 Pieris Pharmaceuticals Gmbh polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2
DK3292137T3 (da) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
MX390894B (es) 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
KR20180008649A (ko) * 2015-05-18 2018-01-24 피어이스 파마슈티컬즈 게엠베하 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인
EP3115066A1 (en) * 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
KR102818445B1 (ko) * 2015-09-23 2025-06-10 브리스톨-마이어스 스큅 컴퍼니 글리피칸-3-결합 피브로넥틴 기반 스캐폴드 분자
EA035586B1 (ru) 2015-11-30 2020-07-10 Пиерис Острелиа Пти Лтд. Новые антиангиогенные слитые белки
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
EP3503930B1 (en) 2016-08-29 2024-12-11 Fred Hutchinson Cancer Center Chelating platform for delivery of radionuclides
CN111542535A (zh) 2017-12-20 2020-08-14 圣安娜儿童癌症研究中心 配体调控的蛋白-蛋白相互作用系统
EP3502130A1 (en) 2017-12-20 2019-06-26 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
CA3127973A1 (en) * 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
AU2021285201A1 (en) 2020-06-05 2022-11-24 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1BB

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
KR20010052622A (ko) 1998-06-08 2001-06-25 프리돌린 클라우스너, 롤란드 비. 보레르 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2002024866A2 (en) * 2000-09-21 2002-03-28 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
WO2009012394A1 (en) 2007-07-17 2009-01-22 Medarex, Inc. Monoclonal antibodies against glypican-3
US8420051B2 (en) * 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)

Similar Documents

Publication Publication Date Title
JP2014502149A5 (cg-RX-API-DMAC7.html)
JP2018532372A5 (cg-RX-API-DMAC7.html)
JP6475630B2 (ja) ストレプトアビジン突然変異タンパク質およびそれらを使用する方法
CN110437320B (zh) 多肽
JP2017518748A5 (cg-RX-API-DMAC7.html)
RU2016149596A (ru) Новые полипептиды со специфическим связыванием и пути их применения
JP2013512683A5 (cg-RX-API-DMAC7.html)
JP2018519802A5 (cg-RX-API-DMAC7.html)
RU2015137158A (ru) МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ
US8426557B2 (en) IGF-1R binding polypeptides and their use
JP2021006024A5 (cg-RX-API-DMAC7.html)
JP2018515084A5 (cg-RX-API-DMAC7.html)
JP2019506140A5 (cg-RX-API-DMAC7.html)
RU2714156C2 (ru) С5-связующие полипептиды
JP2020505948A5 (cg-RX-API-DMAC7.html)
RU2019122482A (ru) Мутеины липокалина с аффинностью связывания в отношении lag-3
AU2014314222B2 (en) Stable polypeptides binding to human complement C5
US7993848B2 (en) Staphylococcus protein A domain mutants that bind to TNF-α
JP2019163270A (ja) 親和性タンパク質及びその使用
JP2019527033A5 (cg-RX-API-DMAC7.html)
JP2004501605A5 (cg-RX-API-DMAC7.html)
JP7553433B2 (ja) 抗ヒト心筋トロポニンiの抗体及びその使用
JP2007535293A5 (cg-RX-API-DMAC7.html)
Kawabata et al. Peptide-based immunoadsorbents: Molecular grafting of IgG–Fc-binding epitopes of Protein A onto a de novo-designed helix-loop-helix peptide
Nice et al. Strategies for the identification and purification of ligands for orphan biomolecules